Dr Reddy’s kicks off India’s big pharma earnings season with a narrow profit miss. The pharmaceutical company reported a profit of Rs 1,409.6 crore, up 1.26 per cent from the same quarter last year (Q1FY25). Revenue rose 11.37 per cent year-on-year to Rs 8,545.2 crore from Rs 7,672.7 crore.
Here are key highlights from Q1FY26 Dr Reddy’s Q1 profit narrowly misses estimates as North America sales dip
Dr Reddy’s consolidated net profit increased to Rs 1,418 crore rupees in the quarter ended June 30, below analysts’ estimate of Rs 1,494 crore, as per data compiled by LSEG cited by Reuters. The company struggled with pricing pressure on drugs and stiff competition in its key North America market. Revenue from Reddy’s biggest market North America fell 11.3% YoY for the Q1FY26 at Rs 3,410 crore.
“The decline was primarily due to increased price erosion in certain key products including Lenalidomide,” the company said in a statement.
Europe revenue jumps 142% on strong NRT demand
Revenue from Europe more than doubled at Rs 1,274 crore, driven by demand for nicotine replacement therapy (NRT), which Dr Reddy’s bought from British drugmaker Haleon in 2024. Revenue from Europe market increased 142 per cent YoY including Rs 670 crore from NRT business.
Rival Cipla is set to report first quarter results on Friday, July 25.
This is a breaking story. More Information will be added soon…
» Read More
